- GlobeNewswire•13 days agoInternational Stem Cell Corporation Announces Operating Results for the Three and Six-Months Ended June 30, 2016
CARLSBAD, Calif., Aug. 16, 2016-- International Stem Cell Corporation, a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business ...
- GlobeNewswire•last monthInternational Stem Cell Corporation Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC
CARLSBAD, Calif., July 28, 2016-- International Stem Cell Corporation, a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced ...
- Capital Cube•3 months ago
Click here to see latest analysisInternational Stem Cell Corp. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of International Stem Cell Corp. – Keryx Biopharmaceuticals, Inc., Opexa Therapeutics, Inc., Celgene Corporation, Anthera Pharmaceuticals, Inc., Chimerix, Inc. and Vericel Corporation (KERX-US, OPXA-US, CELG-US, ANTH-US, CMRX-US and […] (Read more...) The post International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 appeared first on CapitalCube.
International Stem Cell Corporation (ISCO)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||1.95 - 1.99|
|52wk Range||1.90 - 2.14|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.65|
|Avg Vol (3m)||5,124|
|Dividend & Yield||N/A (N/A)|